Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

erest related to the settlement reached with U.S. Attorney's Office.

(8) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(9) To exclude charges related to the acquisition of licensed technology in the oncology field.

(10) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED SALES DETAIL

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2008

United

States Europe Total

Sales:

PROVIGIL $241,366 $17,793 259,159

GABITRIL 12,176 2,337 14,513

CNS 253,542 20,130 273,672

ACTIQ 21,392 14,401 35,793

Generic OTFC 19,569 - 19,569

FENTORA 41,330 - 41,330

AMRIX 20,512 - 20,512

Pain
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NJ (PRWEB) , ... July 29, 2015 , ... The ... approval of combination products , in particular, drug/device combinations. The current system received ... by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ...
(Date:7/29/2015)... ... 29, 2015 , ... Available in select spas and ... nighttime-specific product that targets fat cells for extreme contouring action. During sleep key ... cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down fat ...
(Date:7/28/2015)... -- A n ew ... developing and commercialising innovative medicines to transform patient quality of ... experienced management team; blue chip ... BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces ... gross, from blue chip institutional investors and simultaneously acquired a ...
(Date:7/28/2015)... Mass. , July 28, 2015 ... measuring cell metabolism, is the provider of XF ... across all disease research areas. As the links ... exploration into cell metabolism is escalating rapidly.   ... published by the Nature Publishing Group (NPG) featuring ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... Imaging and Printing Group and its Personal Systems Group into ... milestone in HPs journey to become the consumer ... a unified and convincing product message for every room in ... HPs consumer message into overdrive. , ,The consumer technology market ...
... Merge Technologies Incorporated and Cedara Software Corp. ... develop health-care software, particularly digital medical imaging. , ,Pending stockholder ... in Milwaukee. Merge CEO Richard Linden will stay ... Abe Schwartz will stay on the board of directors. Merge ...
... an idea of what Madison could offer to the field ... how many new visitors our coverage of last Thursday's ... WTN 's Web site. Our normal recurring readership is ... than half are from out-of-state and about 15 percent read ...
Cached Biology Technology:HP charges toward the living room 2HP charges toward the living room 3International eyes drawn to Madison's games research 2International eyes drawn to Madison's games research 3International eyes drawn to Madison's games research 4
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Cold Spring Harbor, NY A team of researchers at ... of DNA called an enhancer element that enables cancerous blood ... cancer that is incurable in 70% of patients. Just ... a new class of promising drugs one version of ...
... Calif. John Trumble , a distinguished professor ... Riverside, has been named the recipient of the 2013 ... and/or extension education benefiting the California vegetable industry. ... problems in agricultural and natural ecosystems, will receive the ...
... in the form of humidity, water spills, or rainfall ... displays, TVs, and solar photovoltaic (PV) panels worldwide. Standing ... a transparent film barrier that must work flawlessly year after ... test that can detect infinitesimally small amounts of moisture ...
Cached Biology News:Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease 2Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease 3Entomologist recognized for exceptional service to California's vegetable industry 2NREL test helps make moisture barriers better 2NREL test helps make moisture barriers better 3NREL test helps make moisture barriers better 4NREL test helps make moisture barriers better 5NREL test helps make moisture barriers better 6NREL test helps make moisture barriers better 7
... , Coated Capture Antibody: 12 x 8-well strips, ... mL of 2X concentrate , Beta Amyloid ... , Lyophilized Standard Diluent: 3 mL , Primary ... Antibody-HRP: 30 microL of concentrate , OPD Substrate: ...
Human Cell Line Slides...
Request Info...
HSV 1 IgM...
Biology Products: